Current Treatment Paradigm: Evolution of First-Line Therapy for ES-SCLC
Panelists discuss how the addition of immune checkpoint inhibitors to first-line chemotherapy has transformed the treatment of extensive-stage small cell lung cancer, improving survival while highlighting ongoing challenges in managing relapse and the need for continued research into novel therapies.
Summary for Physicians:
The treatment landscape for extensive-stage small cell lung cancer (ES-SCLC) has evolved significantly over the past decade.
Historically, platinum-based chemotherapy (typically etoposide with either cisplatin or carboplatin) was the standard of care, offering initial high response rates but limited durability due to rapid disease progression and high relapse rates.
In recent years, the addition of immune checkpoint inhibitors to first-line chemotherapy has changed the standard approach. The combination of chemotherapy with PD-L1 inhibitors (e.g., atezolizumab or durvalumab) has demonstrated improved overall survival and is now considered the first-line standard of care for most patients with ES-SCLC.
Despite these advances, challenges remain, particularly in managing disease recurrence, for which options are limited. Research is ongoing into novel immunotherapy combinations, targeted agents, and biomarkers to further improve outcomes in this aggressive disease.
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
